You are here: Industry Insights > Market News > Claris completes sale of its stake in JV to Otsuka

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

CBZ-L-Valganciclovir

4-Bromo-3-nitroanisole

PF-680Adjustable Cellophane Tri-dimensiona Overwrapping Machine (with tear type)

2-Chlorophenothiazine

Flibanserin

its control software

Claris completes sale of its stake in JV to Otsuka

expressbpdSeptember 26, 2017

Tag: Claris , JV , Otsuka

Favorites

The agreement to sell was announced on May 8, 2017

Claris Lifesciences has recently completed the sale of its remaining 20 per cent stake in Otsuka Pharmaceutical India; the joint venture with Otsuka Pharmaceutical Factory, and Mitsui & Co.; to Otsuka Pharmaceutical Factory, for a consideration of $ 20 million.

In the July, 2017 the company has also completed the sale of its global generic injectables business to Baxter international for an enterprise value of $ 625 million.

Previous:Bayer backs new mobile eye unit in Hampshire

Next:BioAscent Discovery in agreement with Pivot Park Screening Centre

InnoCare Announces Approval of Clinical Trial of a Novel ADC ICP-B794 in China

PharmaSourcesJuly 04, 2025

InnoCare Pharmaannounced the approval of the Investigational New Drug (IND) by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) to conduct the clinical trial of a novel B7-H3 targeted ADC ICP-B794.

CanSinoBIO Launches Pneumococcal Vaccine: An Innovative Choice to Safeguard Children's Health

ACN NewswireJune 20, 2025

LTS and Nualtis Announce Strategic Cooperation to Expand Global Manufacturing Capabilities, Accelerate Market Expansion, and Ensure Customer Success

PR NewswireJune 25, 2025

Claris completes sale of its stake in JV to Otsuka | Pharmasources.com

Hua Medicine Announces at 2025 ADA Scientific Sessions that Dorzagliatin Combined With DPP-4 Inhibitor Shows Promise in Reducing Blood Lipids While Restoring Glucose Homeosta

ACN NewswireJune 23, 2025

Hua Medicine announced today that the Company presented the latest research results of dorzagliatin, its global first-in-class glucokinase activator (GKA), at the 85th Scientific Sessions of the American Diabetes Association (ADA).

久久婷婷国产综合精品,久久久久久久性潮,换脸国产av一区二区三区,韩国精品一区二区三区无码视频 ,久久久久成人精品无码

Claris completes sale of its stake in JV to Otsuka

Related News

InnoCare Announces Approval of Clinical Trial of a Novel ADC ICP-B794 in China

CanSinoBIO Launches Pneumococcal Vaccine: An Innovative Choice to Safeguard Children's Health

LTS and Nualtis Announce Strategic Cooperation to Expand Global Manufacturing Capabilities, Accelerate Market Expansion, and Ensure Customer Success

Hua Medicine Announces at 2025 ADA Scientific Sessions that Dorzagliatin Combined With DPP-4 Inhibitor Shows Promise in Reducing Blood Lipids While Restoring Glucose Homeosta

You may like
More>>

久久婷婷国产综合精品,久久久久久久性潮,换脸国产av一区二区三区,韩国精品一区二区三区无码视频 ,久久久久成人精品无码

Claris completes sale of its stake in JV to Otsuka

Related News

InnoCare Announces Approval of Clinical Trial of a Novel ADC ICP-B794 in China

CanSinoBIO Launches Pneumococcal Vaccine: An Innovative Choice to Safeguard Children's Health

LTS and Nualtis Announce Strategic Cooperation to Expand Global Manufacturing Capabilities, Accelerate Market Expansion, and Ensure Customer Success

Hua Medicine Announces at 2025 ADA Scientific Sessions that Dorzagliatin Combined With DPP-4 Inhibitor Shows Promise in Reducing Blood Lipids While Restoring Glucose Homeosta

You may likeMore>>

You may like
More>>